Repligen (NASDAQ:RGEN) Given New $135.00 Price Target at Jefferies Financial Group

Key Points

• Jefferies Financial Group has lowered the target price for Repligen from $145.00 to $135.00, maintaining a "hold" rating on the stock, which suggests a potential upside of 12.96% from its current price.
• Repligen stock has seen mixed ratings from several analysts, with a consensus target price of $166.67 and a current rating of "Moderate Buy."
• The biotechnology company reported earnings of $0.37 per share for the last quarter, slightly below the consensus estimate, but it achieved year-over-year revenue growth of 14.8%.

Repligen (NASDAQ:RGEN - Get Free Report) had its target price lowered by research analysts at Jefferies Financial Group from $145.00 to $135.00 in a research note issued on Friday,Benzinga reports. The firm presently has a "hold" rating on the biotechnology company's stock. Jefferies Financial Group's price objective points to a potential upside of 12.96% from the company's current price.

RGEN has been the topic of several other reports. Wells Fargo & Company reduced their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. Stephens upgraded Repligen to an "overweight" rating and set a $160.00 price objective on the stock in a research note on Tuesday, July 22nd. Royal Bank Of Canada reiterated an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. Evercore ISI reduced their price objective on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Finally, Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $166.67.

Repligen Stock Down 0.6%

NASDAQ:RGEN opened at $119.51 on Friday. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The stock's fifty day moving average is $121.01 and its two-hundred day moving average is $128.35. Repligen has a 52 week low of $102.96 and a 52 week high of $182.52. The stock has a market capitalization of $6.72 billion, a price-to-earnings ratio of -478.02, a price-to-earnings-growth ratio of 2.21 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm's revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Research analysts anticipate that Repligen will post 1.72 EPS for the current year.

Insider Buying and Selling

In other Repligen news, Director Martin D. Madaus bought 1,800 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the acquisition, the director directly owned 1,800 shares of the company's stock, valued at $201,834. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently made changes to their positions in the company. DekaBank Deutsche Girozentrale grew its holdings in shares of Repligen by 1.0% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,830 shares of the biotechnology company's stock worth $961,000 after purchasing an additional 80 shares during the last quarter. Alliance Wealth Advisors LLC UT grew its holdings in shares of Repligen by 2.5% during the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock worth $468,000 after purchasing an additional 89 shares during the last quarter. Drive Wealth Management LLC grew its holdings in shares of Repligen by 2.5% during the second quarter. Drive Wealth Management LLC now owns 3,796 shares of the biotechnology company's stock worth $472,000 after purchasing an additional 93 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Repligen by 4.3% during the second quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company's stock worth $288,000 after purchasing an additional 96 shares during the last quarter. Finally, State of Michigan Retirement System grew its holdings in shares of Repligen by 0.8% during the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock worth $1,585,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.